TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company”) (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) is pleased to announce that it will hold its annual general and special meeting of shareholders on September 15, 2026 (the “Meeting”) to seek shareholder approval for

“Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange (“TSXV”).

TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological support for ExoPTEN’s potential neuroprotective effect in an animal model

TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top“), together with the Company, has signed a binding memorandum

TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.

TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds

TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a